An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

Autor: Oø Bruland, Michael W. Kattan, Svein Inge Helle, Sten Nilsson, L. Xu, Daniel Heinrich, Joe M. O'Sullivan, Robert E. Coleman, M. Shan, Oliver Sartor, Scott Wilhelm, Nicholas J. Vogelzang, S. Kobina, Chris Parker
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Male
radium-223
Kaplan-Meier Estimate
Gastroenterology
030218 nuclear medicine & medical imaging
Prostate cancer
chemistry.chemical_compound
0302 clinical medicine
CRPC
education.field_of_study
Bone metastasis
Hematology
Prognosis
Prostate-specific antigen
Prostatic Neoplasms
Castration-Resistant
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Alkaline phosphatase
Kallikreins
Urogential Tumors
medicine.drug
Radium
Radium-223
medicine.medical_specialty
Population
Placebo
03 medical and health sciences
SDG 3 - Good Health and Well-being
Internal medicine
Lactate dehydrogenase
medicine
Journal Article
Biomarkers
Tumor
Humans
education
Proportional Hazards Models
L-Lactate Dehydrogenase
business.industry
lactate dehydrogenase
Original Articles
Prostate-Specific Antigen
medicine.disease
Alkaline Phosphatase
Surgery
chemistry
Multivariate Analysis
ALSYMPCA
Radiopharmaceuticals
business
Zdroj: Annals of Oncology
Sartor, O, Coleman, R E, Nilsson, S, Heinrich, D, Helle, S I, O'Sullivan, J M, Vogelzang, N J, Bruland, Ø, Kobina, S, Wilhelm, S, Xu, L, Shan, M, Kattan, M W & Parker, C 2017, ' An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 ', Annals of Oncology . https://doi.org/10.1093/annonc/mdx044
ISSN: 1569-8041
0923-7534
DOI: 10.1093/annonc/mdx044
Popis: Background Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, such as radium-223, is not established. Patients and methods The radium-223 ALSYMPCA trial enrolled patients with CRPC and symptomatic bone metastases. Prognostic potential of baseline variables was assessed using Cox models. Percentage changes in biomarker levels from baseline were evaluated during the trial period; changes from baseline to week 12 were evaluated for association with OS and surrogacy. Results Eastern Cooperative Oncology Group performance status, total alkaline phosphatase (tALP), lactate dehydrogenase (LDH), and prostate-specific antigen (PSA) at baseline were associated with OS (P ≤ 0.0003) in the intent-to-treat population (radium-223, N = 614; placebo, N = 307). tALP declined from baseline within 4 weeks after beginning radium-223, by week 12 declining in 87% of radium-223 and 23% of placebo patients (P
Databáze: OpenAIRE
Externí odkaz: